Enhanced platelet MRP4 expression and correlation with platelet function in patients under chronic aspirin treatment
暂无分享,去创建一个
O. Turriziani | L. Frati | M. Mancone | G. Sardella | L. Lotti | S. Calcagno | I. Massimi | F. Pulcinelli | F. Temperilli | Simone Calcagno
[1] B. Giusti,et al. High on-aspirin platelet reactivity predicts cardiac death in acute coronary syndrome patients undergoing PCI. , 2016, European journal of internal medicine.
[2] L. Frati,et al. Nonsteroidal anti-inflammatory drugs in-vitro and in-vivo treatment and Multidrug Resistance Protein 4 expression in human platelets. , 2016, Vascular pharmacology.
[3] J. Schuetz,et al. The ABCC4 membrane transporter modulates platelet aggregation. , 2015, Blood.
[4] C. Denis,et al. Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice. , 2015, Blood.
[5] A. Montemari,et al. Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment , 2015, Platelets.
[6] D. Voora,et al. Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics , 2015, Pharmacogenomics and personalized medicine.
[7] D. Angiolillo,et al. Aspirin treatment and outcomes in patients undergoing percutaneous coronary intervention: is there a role for pharmacodynamic testing? , 2014, Journal of the American College of Cardiology.
[8] H. Schunkert,et al. Aspirin treatment and outcomes after percutaneous coronary intervention: results of the ISAR-ASPI registry. , 2014, Journal of the American College of Cardiology.
[9] Shih-Yi Huang,et al. Multidrug resistance protein 4 (MRP4/ABCC4) regulates thrombus formation in vitro and in vivo. , 2014, European journal of pharmacology.
[10] Pankaj Sharma,et al. Increased platelet expression of glycoprotein IIIa following aspirin treatment in aspirin-resistant but not aspirin-sensitive subjects. , 2014, British journal of clinical pharmacology.
[11] C. Gaudio,et al. Aspirin influences megakaryocytic gene expression leading to up-regulation of multidrug resistance protein-4 in human platelets , 2014, British journal of clinical pharmacology.
[12] A. Ferro,et al. Mechanisms of aspirin resistance. , 2014, Pharmacology & therapeutics.
[13] W. Kraus,et al. Aspirin exposure reveals novel genes associated with platelet function and cardiovascular events. , 2013, Journal of the American College of Cardiology.
[14] A. Borgognone,et al. Reduction of cAMP and cGMP inhibitory effects in human platelets by MRP4-mediated transport , 2012, Thrombosis and Haemostasis.
[15] C. Gaudio,et al. Aspirin extrusion from human platelets through multidrug resistance protein-4-mediated transport: evidence of a reduced drug action in patients after coronary artery bypass grafting. , 2011, Journal of the American College of Cardiology.
[16] J. T. ten Berg,et al. High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention , 2011, Heart.
[17] A. Kaltoft,et al. Patients with previous definite stent thrombosis have a reduced antiplatelet effect of aspirin and a larger fraction of immature platelets. , 2010, JACC. Cardiovascular interventions.
[18] Andrew D. Johnson,et al. Relation of Platelet and Leukocyte Inflammatory Transcripts to Body Mass Index in the Framingham Heart Study , 2010, Circulation.
[19] M. Furman,et al. Association of Cyclooxygenase-1–Dependent and –Independent Platelet Function Assays With Adverse Clinical Outcomes in Aspirin-Treated Patients Presenting for Cardiac Catheterization , 2009, Circulation.
[20] F. Santilli,et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". , 2009, Journal of the American College of Cardiology.
[21] B. Giusti,et al. Thrombotic events in high risk patients are predicted by evaluating different pathways of platelet function , 2008, Thrombosis and Haemostasis.
[22] Deepak L. Bhatt,et al. Incomplete Inhibition of Thromboxane Biosynthesis by Acetylsalicylic Acid: Determinants and Effect on Cardiovascular Risk , 2008, Circulation.
[23] F. Sofi,et al. Residual platelet reactivity on aspirin therapy and recurrent cardiovascular events--a meta-analysis. , 2008, International journal of cardiology.
[24] W. Gianni,et al. Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. , 2008, Current cancer drug targets.
[25] W Scott Beattie,et al. Aspirin “resistance” and risk of cardiovascular morbidity: systematic review and meta-analysis , 2008, BMJ : British Medical Journal.
[26] New European guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction--what are the new and key messages. , 2007, Polskie Archiwum Medycyny Wewnetrznej.
[27] J. Eikenboom,et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. , 2007, Archives of internal medicine.
[28] Colin Baigent,et al. Low-dose aspirin for the prevention of atherothrombosis. , 2005, The New England journal of medicine.
[29] F. Violi,et al. Persistent production of platelet thromboxane A2 in patients chronically treated with aspirin , 2005, Journal of thrombosis and haemostasis : JTH.
[30] A. Weyrich,et al. Neutrophils alter the inflammatory milieu by signal-dependent translation of constitutive messenger RNAs. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[31] P. Gazzaniga,et al. Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients. , 2004, Journal of the American College of Cardiology.
[32] B. Goh,et al. Multidrug resistance protein 4 (MRP4/ABCC4) mediates efflux of bimane-glutathione. , 2004, The international journal of biochemistry & cell biology.
[33] E. Topol,et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. , 2003, Journal of the American College of Cardiology.
[34] S. Yusuf,et al. Aspirin-Resistant Thromboxane Biosynthesis and the Risk of Myocardial Infarction, Stroke, or Cardiovascular Death in Patients at High Risk for Cardiovascular Events , 2002, Circulation.
[35] P. Gazzaniga,et al. Evidence for separate effects of U73122 on phospholipase C and calcium channels in human platelets. , 1998, Biochemical pharmacology.
[36] G. FitzGerald,et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. , 1983, The Journal of clinical investigation.
[37] G. Born,et al. Aggregation of Blood Platelets by Adenosine Diphosphate and its Reversal , 1962, Nature.